- TBS Osteo Advanced next-generation software rolled out across Europe, addressing osteoporosis in a disease affecting over 32 million Europeans
- Broad clinical adoption reinforces TBS Osteo's leadership in bone microarchitecture evaluation for fracture risk assessment
- Subscription-based model offers ongoing services and access to future clinical innovations
Geneva, Switzerland — July 3, 2025
Medimaps — the creator of TBS® (Trabecular Bone Score®), the global standard in bone microarchitecture assessment — today announced the European launch of its MDR-cleared, next-generation TBS Osteo™ Advanced software. Following the product’s launch in the United States the previous month, this milestone reflects the company’s commitment to advancing osteoporosis detection and bone health management worldwide.
TBS Osteo™ Advanced delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring the inclusivity of TBS® assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage TBS® software across their DXA systems fleet and standardize workflows across multiple locations — enhancing operational efficiency and ensuring consistent patient care.
TBS Osteo™ is available through a subscription model, giving customers ongoing eligibility for software updates, new features, and support services, so healthcare organizations stay current with the latest innovations in osteoporosis care. Existing TBS Osteo™ users can upgrade to the next-generation version to access the new capabilities.
"The TBS Osteo next-generation software has been developed with busy radiology professionals in mind, for maximum clinical output with a minimum of logistics. The software is seamlessly integrated into the clinical workflow and performed at the time of the DXA scan. This approach sets TBS Osteo apart from the competition. TBS Osteo delivers, within seconds, a comprehensive report combining BMD and clinical factors, providing results beyond the standard of care. Adopted by many top hospitals across the world, including in the US, DXA and TBS Osteo have become the gold standard to detect and monitor osteoporosis."
said Didier Hans, CEO and Co-founder of Medimaps.
Since its initial launch in 2012, TBS Osteo™ has been widely adopted across the world to support the assessment and management of osteoporosis. The software is backed by over 1,400 peer-reviewed publications and endorsed by more than 30 national and international osteoporosis assessment and management guidelines.
In Europe, the software has received clearance under the Medical Device Regulation (MDR) and remains the only approved medical software for bone microarchitecture evaluation using TBS® in clinical practice.
Osteoporosis is a condition that weakens bones and increases the risk of fractures, with a devastating impact on millions of people worldwide and enormous socio-economic costs to healthcare systems.
According to the International Osteoporosis Foundation, approximately 32 million Europeans aged 50 or over have osteoporosis. The annual number of osteoporotic fractures across the European Union, Switzerland, and the United Kingdom is projected to rise from 4.33 million in 2019 to 5.34 million by 2034 — an increase of over 1 million fractures annually.¹ Despite the availability of effective treatments to reduce fracture risk, nearly 1 in 5 patients who experience an osteoporotic fracture are diagnosed or receive appropriate therapy.¹
Reference:
1. International Osteoporosis Foundation (IOF). https://www.osteoporosis.foundation/facts-statistics/key-statistic-for-europe